BLT - Blis Technologies

[emearg]

You may find if you search that there are multiple patents with different expiry dates. I know this is the case for Q24 because I looked a while back.

[nevchev]

Key Players Mentioned in the Global Special Probiotic Strains Market Research Report: DuPont, Chr. Hansen, Lallemand, BioGaia, Probi, Cerbios – Pharma, Morinaga Milk Industry, Protexin, Blis Technologies, Cultech, Bifodan, Probiotical, Kerry Group, PrecisionBiotics, Unique Biotech, Biosearch Life, Synbiotech, Wecare-Bio

I found 3 available probiotic market research papers for purchase last night that include Blis Tech alongside some big players including Dupont.I think we are gaining recognition and are quite respected for our work regarding probiotic research.Well done team

[Brain]

Key Players Mentioned in the Global Special Probiotic Strains Market Research Report: DuPont, Chr. Hansen, Lallemand, BioGaia, Probi, Cerbios – Pharma, Morinaga Milk Industry, Protexin, Blis Technologies, Cultech, Bifodan, Probiotical, Kerry Group, PrecisionBiotics, Unique Biotech, Biosearch Life, Synbiotech, Wecare-Bio

I found 3 available probiotic market research papers for purchase last night that include Blis Tech alongside some big players including Dupont.I think we are gaining recognition and are quite respected for our work regarding probiotic research.Well done team

That list of names makes me even more concerned about Patent protection.

[nevchev]

That list of names makes me even more concerned about Patent protection.

Try searching here brain.im on my phone and it wont allow a search
WIPOhttp://www.wipo.int/pctdb/en/
Im more concerned about been one of the big players snapping us up before we even get going

[patrick]

Surely the Company’s who purchase ingredients from Blis could combine efforts to save some dollars as Patents expire?
It is a concern for me, but hope others are correct.

[nevchev]

Kalkine Media ASX Share Market News & Research
Home Editorial
5 Disruptive Trends Amidst Re-opening of NZ Economy: Caution Ahead
Jul 02, 2020 NZST Team Kalkine
5 Disruptive Trends Amidst Re-opening of NZ Economy: Caution Ahead
Summary
The long-term continuation of the transformation during lockdown is expected with the change in psychological attitude and behaviour of customers
Driven by the supply chain challenges amid COVID-19, IoT and Automation lead fleet management and production has garnered greater attention.
New Zealand’s stand on ensuring safety against the pandemic indicates that the country is expected to witness prolongation of similar practices.
“Come hell or high water” - New Zealand appears to be ready to ride out the storm thrown by the health crisis. The country’s successful accomplishments built on its aggressive, yet strategic route undoubtedly recounts the triumphs and future promises for Kiwiland poised to rebuild the economy.

Prime Minister Jacinda Ardern’s ‘little dance’ which she mentioned as an immediate reaction on acknowledging New Zealand as ‘Coronavirus-free’ echoes the optimistic sentiments of the country amidst the pandemic.

Although new infection cases have emerged, possibly due to the return of the overseas New Zealanders as anticipated by the Government and authorities, the country is much better positioned to restart its economy, thanks to the disruptions geared against health threats, cushioning the impact of coronavirus and lockdown restrictions.

ALSO READ: Leaf Through Emerging Trade Trends Underlining Potential for NZ Businesses

Jacinda Ardern in her latest statement maintained a similar stance indicating that until it has “reassurances that New Zealanders will be safe”, the Government would not move ahead to resume trans-Tasman travel.

New Zealand has left the decision for bubble creation “up to Australia”, leaving the latter the option to decide whether or not to open travel with the whole country or individual states. Notably, Victoria recently witnessed a spike in the cases which seems to generate concerns on the second wave of infection in the Australian state.

However, New Zealand, with no plan for opening borders for other countries, would be conducting a virtual APEC summit, hinting the transition towards a new normal created by new-fangled realities and budding conditions.

On that backdrop, let us look at the trends that are emerging and raising bars for competition in the severe economic scenario.

Digital Shopping

Post the coronavirus outbreak, E-commerce, often known to tout and challenge traditional business models, has massively overcome the psychological inertia of many customers who earlier resisted breaking the chain of their old habits of not adopting the electronic medium of payment and shopping. The need for social distancing and the emerging digital payment methods have opened up greater avenues for online shopping.



Healthcare Evolution

Healthcare sector remained under the radar incorporating changes for confronting the pandemic for wading possible threats of crisis. Telehealth and virtual consultations have evolved primarily as people during the lockdown and even after it shied away from venturing outside.

The consumers driven by the health concerns were found to prefer health-related or immunity-boosting products. Meanwhile, the massive concern for the frontline health workers who remain primarily exposed to the infection has driven the vast revolution involving real-time monitoring and use of robotics.

The biotechnology company, Blis Technologies Limited (NZX: BLT) has continued to build the BLIS® Probiotics brand. It has increased its production capacity for meeting COVID-19 driven demand. The company indicated that consumer interest in solutions to maintain health and wellbeing is providing a robust opportunity for Blis Technologies.

[nevchev]

Seems BLTs arrangement with Stratum was fore ingredients only which explains growth in sales of this segment of their business.Found this from 2015


“Stratum is primarily an ingredient business whereas BLIS has been steadily adding a range of finished product. We want to retain the expertise of Stratum in that North American ingredients market but become more directly involved in finished product markets in Europe and Asia. At this stage we have no intent to develop a North American presence in finished product. We have enough to do in Europe and Asia.”

Working with Stratum, BLIS has been experiencing growth in ingredient sales, particularly in North America. Dr Richardson said the company’s increasing ingredient sales over the past 12 months is primarily due to consumer product sales with BLIS K12 although BLIS M18 is also starting to get greater attention.

Stratum Nutrition president Jeremy Moore said Stratum has always been committed to empowering manufacturers and marketers to innovate with confidence by providing progressive, safe and reliable ingredients like BLIS K12 and BLIS M18.

“It is not within our strategic scope to be involved in finished products. We are pleased to continue offering these ground-breaking technologies to our customers throughout North America,” Moore said.

[nevchev]

Seems we dont sell any finished product in the northern hemisphere except what is sold on amazon.Bluestone Pharma(Europe) have Blis k12 and m18 in their own products---Dentoblis,Bactoblis and Freshblis.We are alot more relient on ingredient sales than i relized.Its not a bad thing as far as i can see

[emearg]

Seems BLTs arrangement with Stratum was fore ingredients only which explains growth in sales of this segment of their business.Found this from 2015


“Stratum is primarily an ingredient business whereas BLIS has been steadily adding a range of finished product. We want to retain the expertise of Stratum in that North American ingredients market but become more directly involved in finished product markets in Europe and Asia. At this stage we have no intent to develop a North American presence in finished product. We have enough to do in Europe and Asia.”

Working with Stratum, BLIS has been experiencing growth in ingredient sales, particularly in North America. Dr Richardson said the company’s increasing ingredient sales over the past 12 months is primarily due to consumer product sales with BLIS K12 although BLIS M18 is also starting to get greater attention.

Stratum Nutrition president Jeremy Moore said Stratum has always been committed to empowering manufacturers and marketers to innovate with confidence by providing progressive, safe and reliable ingredients like BLIS K12 and BLIS M18.

“It is not within our strategic scope to be involved in finished products. We are pleased to continue offering these ground-breaking technologies to our customers throughout North America,” Moore said.

Before Stratum they hooked up with Frutarom in 2008 as their ingredients distributor. There were many new products launched in 2008 and beyond. America got a M18 product several years before it was available in NZ

If you have questions you're welcome to ask here...some of us have long memories and pretty detailed knowledge of Blis and their journey.

Until recently Blis was stuck just selling their own product into NZ. It was/is a pretty small market. Over the past few years they have branched out a bit and are clearly trying to build their direct brand presence in other countries as their resources allow it. Ingredients seemed to be their future a decade ago, and in my opinion ideally still will be if and when Blis K12 and/or 18 makes it into functional foods. That could be a nice earner for them, and take the products beyond lozenges.

The wheels on Blis spin very slowly. They have started to spin a little quicker over the past few years, but not as quick as some folks on this thread are perhaps anticipating?

[emearg]

It would be interesting to ask at the AGM how the rollout through the Sinopharm pharmacies in China is going. Has it stalled? Did it get canned? We haven't heard squat about this for a couple of years.